AltPep Corporation developed first-of-its-kind SOBA-AD assay, a simple blood test for the detection of Alzheimer’s Disease.
SOBA-AD assay is a blood test conducted to detect toxic oligomers which triggers rapid events associated with AD, such as cognitive impairment and neurodegeneration. Moreover, the SOBA-AD assay has the ability to recognise the disease early, even before symptoms arise. Early detection of AD may lead to more effective treatments that limit cognitive decline in patients.
Current FDA-cleared diagnostic tests for Alzheimer’s Disease (AD) repeat amyloid-beta plaques and neurofibrillary tangles in the brains of patients whereas SOBA-AD test detects the early molecular triggers of the disease, before plaque formation.
Alzheimer’s disease is the most widely spread form of demantia affecting currently 6 million Americans and expected to grow to 13 million in the future.
U.S. Food and Drug Administration (FDA) grants Breakthrough Device designation for its SOBA-AD diagnostic test for Alzheimer’s disease (AD).
